.jpg "Galectin Therapeutics (NASDAQ: GALT)")
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (NASDAQ: GALT) today and set a price target of $12. The company’s shares closed yesterday at $6.93.
Arce wrote:
“We employ a risk-adjusted net present value (rNPV) model, driven by the U.S. and EU-5 sales of GR-MD-02 for NASH cirrhosis through 2031 (45.0% POS, peak sales $1.4B; zero terminal value), discounted at 17.0%.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 22.3% and a 44.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galectin Therapeutics with a $12 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.49 and a one-year low of $1.28. Currently, Galectin Therapeutics has an average volume of 736.4K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2018, Jack Callicutt, the CFO of GALT sold 226,000 shares for a total of $1,945,802.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments.
